Biodesix (BDSX) Liabilities and Shareholders Equity (2019 - 2026)

Biodesix (BDSX) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $94.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 9.74% year-over-year to $94.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $358.6 million (down 10.82% YoY) and the FY2025 annual result came in at $87.5 million, down 10.04% from the prior year.
• Liabilities and Shareholders Equity rose to $94.6 million in Q1 2026, from $87.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $115.8 million in Q2 2024 to a low of $61.7 million in Q1 2022.
• A 5-year average of $87.4 million and a median of $87.5 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity plunged 46.62% — and 2024, when it surged 49.24%.
• Tracing BDSX's Liabilities and Shareholders Equity over 5 years: stood at $92.9 million in 2022, then rose by 6.66% to $99.1 million in 2023, then slipped by 1.87% to $97.2 million in 2024, then retreated by 10.04% to $87.5 million in 2025, then climbed by 8.19% to $94.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $94.6 million (Q1 2026), $87.5 million (Q4 2025), and $88.7 million (Q3 2025), per Business Quant data.